It would seem we are all on the same page with this management team and where both companies are at present. Absolutely no one either institutional or accredited believes one word that RVX management tells the market,,,its all still very much a coin toss. Dead money out for years most likely. 5 years post BoM already and seemingly almost total inactivity and they never even attempt to make an apology to their non-accredited investors who have been with them for 2 GD decades. Its all the markets fault as noted (see below), all DMcC's bovine excrement imo. The story is so long in the tooth at this point its embarrassing only to us lifers now! Growing old with inflamation, and additional pain caused by this inept team of slackers is just a slap in the face at this point!

These are just the 2024 IPO fundings in these difficult market conditions to date, not to mention raises for pre-trials etc;

https://www.labiotech.eu/recent-biotech-fundings/?nab=0

January 2024:

• Dyne Therapeutics (United States): $300 million public offering | oligonucleotide therapeutics | phase 1/2 in myotonic dystrophy type 1
• Kymera Therapeutics (United States): $275 million public offering | targeted protein degradation | phase 2 in hidradenitis suppurativa and atopic dermatitis
• Praxis Precision Medicines (United States): $150 million public offering | precision medicine | clinical in pediatric patients with early-onset SCN2A developmental and epileptic encephalopathy
• Dyne Therapeutics (United States): $345.1 million public offering | muscle disease therapies | clinical in myotonic dystrophy type 1
• XORTX (Canada): $2 million public offering | orphan disease indications | phase 2 in polycystic kidney disease
• Immatics (Germany): $175 million public offering | phase 1 in recurrent and refractory solid tumors
• Viridian Therapeutics (United States): $150 million public offering | antibody discovery and engineering | phase 3 in thyroid eye disease
• TransCode Therapeutics (United States): $7.25 million public offering | clinical in metastatic cancer
• Vaxcyte (United States): $750 million public offering | pneumococcal conjugate vaccines | phase 2 in pneumococcal disease
• CG Oncology (United States): $380 million IPO | targeted oncolytic immunotherapy | phase 3 in bladder cancer
• ArriVent Biopharma (United States): $175 million IPO | cancer therapeutics | phase 3 in non-small cell lung cancer
• Tourmaline Bio (United States): $172.5 million public offering | immune and inflammatory disease therapies | phase 2 in thyroid eye disease
• Panbela Therapeutics (United States): $9 million public offering | cancer therapies | phase 3 in pancreatic cancer

February 2024: 

• Vaxcyte (United States): $862.5 million public offering | vaccine technology | phase 2 in pneumococcal disease
• Vera Therapeutics (United States): $250 million public offering | immunologic disease therapeutics | phase 3 in IgA nephropathy
• Alto Neuroscience (United States): $128.6 million IPO | precision medicine | phase 2b in major depressive disorder
• Fractyl Health (United States): $110.0 million IPO | metabolic therapeutics | preclinical in obesity
• Corbus Pharmaceuticals (United States): $94.5 million public offering | precision oncology | IND clearance in solid tumors |
• Immix Biopharma (United States): $15 million public offering | cell therapy | phase 1b/2a in relapsed/refractory amyloidosis and relapsed/refractory multiple myeloma
• Kyverna Therapeutics (United States): $319 million IPO | cell engineering | phase 2 in B-cell driven autoimmune diseases
• Metagenomi (United States): $93.75 million IPO | precision genetic medicines | preclinical in hemophilia A
• PepGen (United States): $80.1 million public offering | gene therapies | phase 2 in Duchenne muscular dystrophy
• Tenax Therapeutics (United States): $9 million public offering | precision medicine | phase 3 in acute decompensated heart failure
• Larimar Therapeutics (USA): $150 million public offering | rare disease therapeutics | phase 1 in Friedreich’s ataxia
• Iovance Biotherapeutics (USA): $211 million underwritten offering | phase 3 in melanoma

March 2024: 

• Viking Therapeutics (USA): $550 million public offering | metabolic and endocrine disorder therapies | phase 2b in nonalcoholic steatohepatitis.
• BioVie (USA): $21 million public offering | liver and neurodegenerative disease therapeutics | phase 3 in Alzheimer’s disease.
• Apogee Therapeutics (United States): $420 million public offering | biologics | phase 1 in atopic dermatitis
• Eupraxia Pharmaceuticals (Canada): C$30 million ($22.23 million) public offering | precision medicine | phase 2 in osteoarthritis
• Cognition Therapeutics (United States): $11.5 million public offering | CNS therapies | phase 2 in mild to moderate Alzheimer’s disease
• Nkarta (United States): $240 million public offering | CAR NK cell therapies | phase 1 in lupus nephritis

April 2024: 

• Praxis Precision Medicines (United States): $200 million public offering | central nervous system therapies | phase 3 in essential tremor
• Boundless Bio (United States): $100 million initial public offering | precision oncology | phase 1 in oncogene-related cancers
• Stoke Therapeutics (United States): $125 million public offering | RNA-based medicines | phase 1/2 in Dravet syndrome
• Contineum Therapeutics (United States) : $110 million IPO | small molecules | phase 1 in idiopathic pulmonary fibrosis and multiple sclerosis
• Longeveron (United States) : $5.25 million public offering | cell therapies | phase 2 in hypoplastic left heart syndrome
• Nurix Therapeutics (United States) : $175 million public offering | small molecules and antibody therapies | phase 1 in B-cell cancers
• TScan Therapeutics (United States) : $150 million public offering | T cell receptor therapies | phase 1 in blood cancers
• Biohaven (United States) : $230 million public offering | neuroscience and cancer drugs | phase 3 in obsessive compulsive disorder
• Longeveron (United States) : $11.4 million public offering | cell therapies | phase 2 in hypoplastic left heart syndrome
• Mustang Bio (United States) : $4 million public offering | cell and gene therapies | phase 1 in non-Hodgkin lymphoma and chronic lymphocytic leukemia

May 2024:

• Soleno Therapeutics (United States): $138 million public offering | rare disease therapies | phase 3 in Prader-Willi syndrome
• Dyne Therapeutics (United States): $325.5 million public offering | muscle-targeted therapies | phase 1/2 in myotonic dystrophy type 1
• Monte Rosa Therapeutics (United States): $100 million public offering | molecular glue degraders | phase 1/2 in MYC-driven cancers
• Bicycle Therapeutics (United Kingdom): $555 million PIPE | precision medicine | phase 3 in urothelial cancer
• CARGO Therapeutics (United States): $110 million PIPE | cancer cell therapies | phase 2 in cancer

June 2024:

• Insmed (USA): $650 million public offering | rare disease therapeutics | phase 3 in MAC lung disease
• Structure Therapeutics (United States): $476 million public offering | chronic disease therapies | phase 2 in obesity
• Rapport Therapeutics (United States): $154 million IPO | small molecules | phase 1 in focal epilepsy
• ProKidney (United States): $130 million public offering | cell therapies | phase 3 in type 2 diabetes
• Annexon (United States): $125 million public offering | complement-mediated disease therapies | phase 3 in Guillain-Barré syndrome
• UroGen Pharma (USA): $107.5 million public offering | bladder cancer therapies | phase 3 in non-muscle invasive bladder cancer
• Rezolute (USA): $60 million public offering | rare disease therapies | phase 3 in congenital hyperinsulinism
• Alumis (United States): $250 million initial public offering | precision medicine | phase 2 in psoriasis

July 2024: 

• IDEAYA Biosciences (United States) : $263 million public offering | precision medicine | phase 2 in ocular melanoma
• Artiva Biotherapeutics (USA): $167 million IPO | cell therapies | phase 1 in systemic lupus erythematosus
• TransCode Therapeutics (USA): $3 million public offering | RNA therapeutics | clinical in metastatic tumors
• Verastem Oncology (USA): $55 million public offering | cancer therapies | phase 3 in recurrent low-grade serous ovarian cancer

August 2024:

• Ocugen (United States): $35 million public offering | gene and cell therapies | phase 3 in retinitis pigmentosa
• Mind Medicine (United States): $75 million public offering | neurological disease therapies | phase 2 in anxiety disorder
• Zevra Therapeutics (United States): $60 million public offering | rare disease therapeutics | NDA submitted for Niemann-Pick disease Type C
• Precigen (United States): $30 million public offering | gene and cell therapies | phase 2 in recurrent respiratory papillomatosis
• Ocugen (United States): $35 million public offering | gene and cell therapies | phase 3 in retinitis pigmentosa
• Actuate Therapeutics (United States): $22.4 million IPO | cancer therapies | phase 2 in pancreatic cancer
• Avidity Biosciences (United States): $300.1 million public offering | RNA therapeutics | phase 3 in myotonic dystrophy type 1
• Kymera Therapeutics (United States): $225 million public offering | targeted protein degradation | phase 2 in hidradenitis suppurativa and atopic dermatitis

September 2024:

• Vaxcyte (United States): $1.3 billion public offering | vaccines | phase 2 in pneumococcal disease
• Ionis (United States): $500.3 million public offering | RNA technology | phase 3 in Alexander disease
• BioCardia (United States): $7.2 million public offering | cell therapies | phase 3 in ischemic heart failure
• Nuvalent (United States): $350 million public offering | kinase inhibitors | phase 2 in non-small cell lung cancer
• Bicara Therapeutics (United States): $315 million initial public offering | bifunctional therapies | phase 1 in head and neck squamous cell carcinoma
• Zenas BioPharma (United States): $225 million initial public offering | immunology-based therapies | phase 3 in immunoglobin G4-related disease
• Viridian Therapeutics (United States): $225 million public offering | antibody therapeutics | phase 3 in thyroid eye disease
• Xencor (United States): $175 million public offering | engineered antibodies | phase 2 in prostate cancer
• MBX Biosciences (United States): $163.2 million initial public offering | precision peptide therapies | phase 2 in hypoparathyroidism
• Kairos Pharma (United States): $6.2 million initial public offering | cancer therapies | phase 2 in prostate cancer
• BioVie (United States): $3 million public offering | drug development | phase 2 in Alzheimer’s disease